Drug Table - Misc Agents Flashcards Preview

Pharm Drug Table > Drug Table - Misc Agents > Flashcards

Flashcards in Drug Table - Misc Agents Deck (76)
Loading flashcards...
1

Imatinib (Gleevac) Class

Tyrosine Kinase
inhibitor

2

Imatinib (Gleevac) Mechanism

Inhibits Abl kinase by binding where ATP
should go; also inhibits PDGFR and c-kit;
metabolized by cytochrome P450

3

Imatinib (Gleevac) Therapeutics

First line therapy for CML; also,
gastrointestinal tumor (GIST)

4

Imatinib (Gleevac) Imp Side effects

Nausea and vomiting, fluid
retention, muscle cramps,
arthralgia

5

Imatinib (Gleevac) Other side effects

Myelosuppression

6

Imatinib (Gleevac) Misc

Oral (1/day)

7

Gefitinib (Iressa) Class

Tyrosine Kinase
inhibitor

8

Gefitinib (Iressa) Mechanism

Inhibit epidermal growth factor receptor
(EGFR) tyrosine kinase

9

Gefitinib (Iressa) Therapeutics

Non-small lung cancer

10

Erlotinib (Tarceva) Class

Tyrosine Kinase
inhibitor

11

Erlotinib (Tarceva) Mechanism

Inhibit epidermal growth factor receptor
(EGFR) tyrosine kinase

12

Erlotinib (Tarceva) Therapeutics

Non-small lung cancer

13

Nilotinib (Tasigna) class

Tyrosine Kinase
inhibitor

14

Nilotinib (Tasigna) Mechanism

Inhibits Abl kinase

15

Nilotinib (Tasigna) Therapeutics

Imatinib-resistant CML

16

Nilotinib (Tasigna) Imp side effects

Myelosuppression

17

Nilotinib (Tasigna) other side effects

QT prolongation, hepatotoxicity,
electrolyte abnormalities

18

Nilotinib (Tasigna) misc

Oral (2/day)

19

Dasatinib (Sprycel) class

Tyrosine Kinase
inhibitor

20

Dasatinib (Sprycel) mechanism

Inhibits Abl & Src kinases

21

Dasatinib (Sprycel) therapeutics

Imatinib-resistant CML

22

Dasatinib (Sprycel) Imp side effects

Myelosuppression, bleeding, fluid
retention, pulmonary arterial
hypertension

23

Dasatinib (Sprycel) other side effects

Diarrhea, nausea and vomiting,
weakness, infections

24

Dasatinib (Sprycel) misc

Oral (1/day)

25

Rituximab (Rituxan) class

Monoclonal
antibody

26

Rituximab (Rituxan) mechanism

CD20 B-cell antibody that can directly
activate apoptosis, activate complement, or
activate cell-mediated cytotoxicity (e.g., T
cells, NK cells)

27

Rituximab (Rituxan) therapeutics

Non-Hodgkin's lymphomas

28

Rituximab (Rituxan) imp side effects

Infusion reactions, tumor lysis
syndrome (TLS), severe
mucocutaneous reactions,
progressive multifocal
leukoencephalopathy (PML)

29

Rituximab (Rituxan) other side effects

Skin reactions, irregular
heartbeat, muscle or joint pain

30

Rituximab (Rituxan) misc

Patients need careful monitoring